Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JB2J
|
|||
| Drug Name |
Isatuximab
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Approved | [1] | |
| Plasma cell myeloma [ICD-11: 2A83.1; ICD-10: C90.0] | Phase 3 | [2] | ||
| Company |
SanofiBridgewater, NJ
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | ClinicalTrials.gov (NCT04270409) Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.